previously reported on the development of a novel VEEV inhibitor, ML336, which showed a 24 potent antiviral effect in cell culture models. However, the mechanism of action had yet to be 25 elucidated. Based on the discovery of mutations conferring resistance within nonstructural 26 proteins, we hypothesized that ML336 inhibits viral RNA synthesis. We found that ML336 was 27 able to inhibit VEEV RNA synthesis with an IC50 value of 1.1 nM in a metabolic labelling assay. 
equids. There are currently no treatments or preventatives for VEEV disease. Our group has 23 previously reported on the development of a novel VEEV inhibitor, ML336, which showed a 24 potent antiviral effect in cell culture models. However, the mechanism of action had yet to be 25 elucidated. Based on the discovery of mutations conferring resistance within nonstructural 26 proteins, we hypothesized that ML336 inhibits viral RNA synthesis. We found that ML336 was 27 able to inhibit VEEV RNA synthesis with an IC50 value of 1.1 nM in a metabolic labelling assay.
28
ML336 marginally affected cellular transcription at levels 20,000-fold above the IC50, and did 29 not show any cytotoxicity up to 50 µM. Using a combination of fluorography, strand-specific 30 qRT-PCR, and a metabolic labelling assay, we found that ML336 inhibits the synthesis of all 31 forms of VEEV RNA. Structural analogues of ML336 showed a correlation between their RNA 32 synthesis inhibitory activity and their antiviral activity in cells, leading us to propose that the 33 primary mechanism of action of this class of compounds is viral RNA synthesis inhibition. The 34 activities of ML336 were highly specific to VEEV, without measurable activity against 35 Chikungunya virus. ML336 was efficacious even in a cell-free viral RNA synthesis assay, 36 suggesting a direct interaction with viral proteins.
37
Importance: 38 Venezuelan equine encephalitis virus (VEEV) is a pathogenic alphavirus that circulates in the 39 Americas which can cause a lethal encephalitis in humans and equids. There are currently no 40 Novel VEEV RNA synthesis inhibitor 3 licensed treatments or vaccines for VEEV. Due to the high potential for aerosol infection and 41 severe outcomes, it is classified as an NIAID Category B agent. To address the unmet need for 42 VEEV antivirals, we continue to advance a novel amidine compound, ML336, through medicinal 43 chemistry and mechanism of action (MOA) studies. Here, we present the molecular MOA by 44 which ML336 inhibits VEEV replication using cellular and biochemical approaches. Our data 45 suggest that ML336 is a direct-acting antiviral that inhibits viral RNA synthesis by interfering 46 with the viral replicase complex. Our studies provide new insights into approaches for the America (3), over 109,000 human cases of VEEV were reported, with nearly 1,000 neurological 63 cases and over 500 associated human fatalities. These outbreaks also caused a significant 64 burden to agriculture with over 800,000 reported deaths of VEEV infected equids. 65 In addition to large natural outbreaks, VEEV poses additional threats to the public. 66 Historically VEEV has been developed as an agent of biological warfare and still has potential as 67 a biological weapon. Autoradiograms were developed using a phosphor screen (Kodak K screen) and documented 220 using a Pharos FX plus (BioRad).
222
Cell-based anti-VEEV assay 223 We measured cell death using a CPE assay as previously described (9 We found that VEEV RNA synthesis was detectable at two HPI, and continued until 18 HPI (Fig 2   258 A). VEEV RNA synthesis reached its peak between 6 and 8 HPI and decreased at 10 HPI.
259
The RNA synthesis data was compared to the amount of nsP2 determined by western 260 blotting. We found that nsP2 was detectable beginning at 4 HPI and the levels peaked at 8 HPI.
261
NsP2 was detected until 12 HPI with no change in the amount present (Fig 2 B) . These data on our data from the time-course experiment (Fig 3 A) . The amount of 3HU incorporated into 270 the total isolated RNA was measured and a dose response curve was generated to calculate the 271 IC 50 (Fig 3 A) or with a DMSO control in the presence of 3HU without act D (Fig 3 C) protein which will prevent the production of nsP123/4 and thus negative strand RNA (14, 31).
306
So, the addition of CHX to our RNA synthesis assay allows us to measure positive sense RNA 307 synthesis by the pre-formed viral replicase complex. which is generated by the mature replicase complex. This data supported our hypothesis that 314 ML336 inhibits the RNA synthesis activity of the mature, fully formed replicase complex. were compared with their EC 50-CPE. We also tested an antiviral compound, ML416, of which the 343 main antiviral mechanism is unrelated to viral RNA synthesis inhibition (Fig 5 A) ML336 has no effect on CHIKV RNA synthesis, consistent with its lack of anti-CHIKV activity 351 Previously we determined that compounds based around the ML336 scaffold had no 352 antiviral effect on CHIKV in cell culture assays (33) . Therefore, we hypothesized that ML336 Our lab has previously published on both our discovery of an anti-VEEV hit compound 395 (CID: 15997213), and the development of our current lead amidine compound, ML336 (9-11).
315

ML336 is a potent inhibitor of both positive and negative RNA synthesis of VEEV
396
However, until now, the MOA of these compounds was unknown. Our initial attempts using 397 resistant viruses identified mutations in the N terminal regions of both nsP2 and nsP4. These that ML336 indeed inhibits the production of VEEV RNA. This RNA inhibition was also highly 408 efficient (EC 50 = 1.1 nM), even more so than the initial CPE inhibition described in our initial cell-409 based assay (Fig 3) .
410
This RNA inhibition effect was also present in ML336 analogs that showed potency 411 against VEEV CPE, indicating a relationship between anti-CPE activity and RNA synthesis 412 inhibition. We had also seen previously that ML336 has no effect on a representative Old World 413 alphavirus, CHIKV, in our CPE-based assay. We confirmed that ML336 has no effect on the RNA 414 synthesis activity of CHIKV, even at 4 µM, a concentration 4,000-fold higher than the IC 50 value 415 of ML336 against VEEV in this assay. These data showed that 1) the ML336 scaffold possesses 416 viral RNA synthesis inhibition activity, and 2) the RNA synthesis inhibition activity of the ML336 417 scaffold correlated well with antiviral activity in cells, strongly supporting the conclusion that 418 the major antiviral mechanism of action of these compounds is viral RNA synthesis inhibition.
419
Our argument is also supported by the fact that ML336 did not inhibit the RNA synthesis of 420 CHIKV, a virus for which ML336 has no antiviral effect. 
